445 related articles for article (PubMed ID: 19441865)
1. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
Chaudhaery SS; Roy KK; Saxena AK
J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
[TBL] [Abstract][Full Text] [Related]
2. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis.
Roy KK; Dixit A; Saxena AK
J Mol Graph Model; 2008 Sep; 27(2):197-208. PubMed ID: 18515163
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
Akula N; Lecanu L; Greeson J; Papadopoulos V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors.
Shen LL; Liu GX; Tang Y
Acta Pharmacol Sin; 2007 Dec; 28(12):2053-63. PubMed ID: 18031622
[TBL] [Abstract][Full Text] [Related]
6. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
8. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
9. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
10. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
12. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
14. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
18. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]